Lv41
460 积分 2025-02-28 加入
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
4小时前
已完结
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
4小时前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
4小时前
已完结
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
4小时前
已完结
Teclistamab, a B-Cell Maturation Antigen × CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
3个月前
已关闭
2022年第64届美国血液学会（ASH）年会（Poster摘要）
3个月前
已关闭
Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
3个月前
已关闭
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4个月前
已完结
Innovative Anti‐CD38 and Anti‐BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
7个月前
已完结
皖公网安备34019202002308
